JP2025511758A5 - - Google Patents

Info

Publication number
JP2025511758A5
JP2025511758A5 JP2024559214A JP2024559214A JP2025511758A5 JP 2025511758 A5 JP2025511758 A5 JP 2025511758A5 JP 2024559214 A JP2024559214 A JP 2024559214A JP 2024559214 A JP2024559214 A JP 2024559214A JP 2025511758 A5 JP2025511758 A5 JP 2025511758A5
Authority
JP
Japan
Application number
JP2024559214A
Other languages
Japanese (ja)
Other versions
JPWO2023194501A5 (https=
JP2025511758A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/059054 external-priority patent/WO2023194501A1/en
Publication of JP2025511758A publication Critical patent/JP2025511758A/ja
Publication of JP2025511758A5 publication Critical patent/JP2025511758A5/ja
Publication of JPWO2023194501A5 publication Critical patent/JPWO2023194501A5/ja
Pending legal-status Critical Current

Links

JP2024559214A 2022-04-05 2023-04-05 新規腫瘍特異的抗原を標的とする骨髄性障害および急性白血病の処置 Pending JP2025511758A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263327757P 2022-04-05 2022-04-05
US63/327,757 2022-04-05
US202263478068P 2022-12-30 2022-12-30
US63/478,068 2022-12-30
PCT/EP2023/059054 WO2023194501A1 (en) 2022-04-05 2023-04-05 Treatment of myeloid disorders and acute leukemias targeting novel tumor specific antigens

Publications (3)

Publication Number Publication Date
JP2025511758A JP2025511758A (ja) 2025-04-16
JP2025511758A5 true JP2025511758A5 (https=) 2026-04-13
JPWO2023194501A5 JPWO2023194501A5 (https=) 2026-04-13

Family

ID=86226509

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024559214A Pending JP2025511758A (ja) 2022-04-05 2023-04-05 新規腫瘍特異的抗原を標的とする骨髄性障害および急性白血病の処置

Country Status (9)

Country Link
EP (1) EP4504784A1 (https=)
JP (1) JP2025511758A (https=)
KR (1) KR20250042204A (https=)
CN (1) CN119317643A (https=)
AU (1) AU2023250214A1 (https=)
CA (1) CA3255414A1 (https=)
IL (1) IL316118A (https=)
MX (1) MX2024012390A (https=)
WO (1) WO2023194501A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025113635A1 (zh) * 2023-12-01 2025-06-05 上海祥耀生物科技有限责任公司 抗cd84抗体及其用途
CN118440198B (zh) * 2024-04-03 2024-11-15 武汉爱博泰克生物科技有限公司 抗人cd69蛋白的兔单克隆抗体及其应用
CN120678778B (zh) * 2025-05-12 2026-01-27 山东康盛医疗器械股份有限公司 药物组合物在弥漫大b细胞淋巴瘤治疗中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
MX379256B (es) 2013-03-15 2025-03-10 Regeneron Pharma Moleculas biologicamente activas, conjugados de las mismas, y usos terapeuticos.
ES3063961T3 (en) * 2014-02-14 2026-04-21 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
WO2018002902A1 (en) 2016-07-01 2018-01-04 Glaxosmithkline Intellectual Property (No.2) Limited Antibody-drug conjugates and therapeutic methods using the same
EP3793591A1 (en) * 2018-05-17 2021-03-24 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
US12534532B2 (en) * 2018-10-26 2026-01-27 Crage Medical Co., Limited CLL1-targeting antibody and application thereof
US20240180963A1 (en) * 2021-04-05 2024-06-06 Altheia Science S.R.L. Diagnosis and treatment of myeloid disorders and acute leukemias using novel tumor specific antigens

Similar Documents

Publication Publication Date Title
JP2024514830A5 (https=)
BR102022025291A2 (https=)
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
BY13149U (https=)
BY13160U (https=)
BY13140U (https=)
BY13141U (https=)
BY13176U (https=)
BY13143U (https=)
BY13144U (https=)
BY13145U (https=)
BY13175U (https=)